A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulmonary Disease COPD

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umeclidinium (Primary)
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Sponsors GSK

Most Recent Events

12 Apr 2015 Status changed from active, no longer recruiting to completed,as reported by ClinicalTrials.gov.
22 Dec 2014 Planned End Date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
22 Dec 2014 Planned primary completion date changed from 1 Apr 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight